Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in: Clinical and Translational Medicine 1/2018

Open Access 01-12-2018 | Review

Combination therapy to checkmate Glioblastoma: clinical challenges and advances

Authors: Debarati Ghosh, Saikat Nandi, Sonali Bhattacharjee

Published in: Clinical and Translational Medicine | Issue 1/2018

Login to get access

Abstract

Combination therapy is increasingly becoming the cornerstone of current day antitumor therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival post diagnosis and a high rate of disease recurrence. The poor prognosis can be attributed to unique treatment limitations, which include the infiltrative nature of tumor cells, failure of anti-glioma drugs to cross the blood–brain barrier, tumor heterogeneity and the highly metastatic and angiogenic nature of the tumor making cells resistant to chemotherapy. Combination therapy approach is being developed against glioblastoma with new innovative combination drug regimens being tested in preclinical and clinical trials. In this review, we discuss the pathophysiology of glioblastoma, diagnostic markers, therapeutic targeting strategies, current treatment limitations, novel combination therapies in the context of current treatment options and the ongoing clinical trials for glioblastoma therapy.
Literature
1.
Manolagas SC, Kronenberg HM (2014) Reproducibility of results in preclinical studies: a perspective from the bone field. J Bone Miner Res 29(10):2131–2140PubMedCrossRef
2.
Cunanan KM et al (2017) Basket trials in oncology: a trade-off between complexity and efficiency. J Clin Oncol 35(3):271–273PubMedCrossRef
3.
4.
Coleman CN et al (2016) Improving the predictive value of preclinical studies in support of radiotherapy clinical trials. Clin Cancer Res 22(13):3138–3147PubMedPubMedCentralCrossRef
5.
Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13–19PubMed
6.
Bayat Mokhtari R et al (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022–38043PubMed
7.
Paolillo M, Boselli C, Schinelli S (2018) Glioblastoma under siege: an overview of current therapeutic strategies. Brain Sci 8(1):15PubMedCentralCrossRef
8.
Malkki H (2016) Trial Watch: glioblastoma vaccine therapy disappointment in Phase III trial. Nat Rev Neurol 12(4):190PubMedCrossRef
9.
Polivka J Jr et al (2017) Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme. Anticancer Res 37(1):21–33PubMedCrossRef
10.
11.
Ostrom QT et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–ii56PubMedPubMedCentralCrossRef
12.
Koshy M et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212PubMedCrossRef
13.
14.
Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100(12):2235–2241PubMedCrossRef
15.
Ohgaki H et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64(19):6892–6899PubMedCrossRef
16.
17.
18.
Verhaak RG et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110PubMedPubMedCentralCrossRef
19.
20.
Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173PubMedCrossRef
21.
Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820PubMedCrossRef
22.
Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772PubMedCrossRef
23.
24.
Song XY et al (2011) Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 4(7):651–660PubMedPubMedCentral
25.
Schittenhelm J, Psaras T (2010) Glioblastoma with granular cell astrocytoma features: a case report and literature review. Clin Neuropathol 29(5):323–329PubMedCrossRef
26.
27.
28.
Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003PubMedCrossRef
29.
Nakagawachi T et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22(55):8835–8844PubMedCrossRef
30.
Wick W et al (2014) MGMT testing—the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10(7):372–385PubMedCrossRef
31.
32.
33.
Manuel JM et al (2016) Role of concurrent methylation pattern of MGMT, TP53 and CDKN2A genes in the prognosis of high grade glioma. J Carcinog Mutagen 7(1):2CrossRef
34.
35.
Shinojima N et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63(20):6962–6970PubMed
36.
37.
Lai A et al (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2):142–148PubMedCrossRef
38.
Malta TM et al (2018) Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol 20(5):608–620PubMedCrossRef
39.
40.
41.
42.
Hill C, Hunter SB, Brat DJ (2003) Genetic markers in glioblastoma: prognostic significance and future therapeutic implications—Commentary. Adv Anat Pathol 10(4):212–217PubMedCrossRef
43.
44.
Koschmann C, Lowenstein PR, Castro MG (2016) ATRX mutations and glioblastoma: impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol Cell Oncol 3(3):e1167158PubMedPubMedCentralCrossRef
45.
Wiestler B et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126(3):443–451PubMedCrossRef
46.
47.
48.
Hu N, Richards R, Jensen R (2016) Role of chromosomal 1p/19q co-deletion on the prognosis of oligodendrogliomas: a systematic review and meta-analysis. Interdiscip Neurosurg 5:58–63CrossRef
49.
50.
Wang Q et al (2017) Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32(1):42–56.e6PubMedPubMedCentralCrossRef
51.
Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef
52.
Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401PubMedCrossRef
53.
54.
Bao S et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760PubMedCrossRef
55.
56.
57.
Qazi MA et al (2017) Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol 28(7):1448–1456PubMedCrossRef
58.
Osuka S et al (2013) IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 31(4):627–640PubMedCrossRef
59.
60.
Sottoriva A et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110(10):4009–4014PubMedCrossRefPubMedCentral
61.
Inda MD et al (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24(16):1731–1745PubMedPubMedCentralCrossRef
62.
63.
Reinartz R et al (2017) Functional subclone profiling for prediction of treatment-induced intratumor population shifts and discovery of rational drug combinations in human glioblastoma. Clin Cancer Res 23(2):562–574PubMedCrossRef
64.
Venere M et al (2015) The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med. 7(304):304ra143PubMedPubMedCentralCrossRef
65.
Kim H et al (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25(3):316–327PubMedPubMedCentralCrossRef
66.
Bhat KPL et al (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24(3):331–346PubMedCrossRef
67.
Wang R et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833PubMedCrossRef
68.
69.
70.
Hjelmeland AB et al (2011) Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 18(5):829–840PubMedCrossRef
71.
Flavahan WA et al (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529(7584):110–114PubMedCrossRef
72.
Hegi ME et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199PubMedCrossRef
73.
Stommel JM et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287–290PubMedCrossRef
74.
Calabrese C et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82PubMedCrossRef
75.
76.
Anjum K et al (2017) Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed Pharmacother 92:681–689PubMedCrossRef
77.
78.
Chowdhury FA et al (2018) Therapeutic potential of thymoquinone in glioblastoma treatment: targeting major gliomagenesis signaling pathways. Biomed Res Int 2018:4010629PubMedPubMedCentralCrossRef
79.
80.
81.
Shibahara I et al (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15(9):1151–1159PubMedPubMedCentralCrossRef
82.
Brescia P et al (2013) CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 31(5):857–869PubMedCrossRef
83.
Wang CH et al (2011) Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 7(1):69–79PubMedCrossRef
84.
Shin DH et al (2015) Synergistic effect of immunoliposomal gemcitabine and bevacizumab in glioblastoma stem cell-targeted therapy. J Biomed Nanotechnol 11(11):1989–2002PubMedCrossRef
85.
86.
Fan X et al (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28(1):5–16PubMedPubMedCentral
87.
88.
Guryanova OA et al (2011) Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19(4):498–511PubMedPubMedCentralCrossRef
89.
90.
Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 27:563–584PubMedCrossRef
91.
92.
Zhou W et al (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 17(2):170–182PubMedPubMedCentralCrossRef
93.
Bhattacharjee S, Nandi S (2017) Synthetic lethality in DNA repair network: a novel avenue in targeted cancer therapy and combination therapeutics. IUBMB Life 69(12):929–937PubMedCrossRef
94.
Bhattacharjee S, Nandi S (2017) DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway. Cell Commun Signal 15(1):41PubMedPubMedCentralCrossRef
95.
Bhattacharjee S, Nandi S (2016) Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer. Clin Transl Med 5(1):45PubMedPubMedCentralCrossRef
96.
Bhattacharjee S, Nandi S (2018) Rare genetic diseases with defects in DNA repair: opportunities and challenges in orphan drug development for targeted cancer therapy. Cancers (Basel) 10(9):298CrossRef
97.
98.
Weller M, Steinbach JP, Wick W (2005) Temozolomide: a milestone in the pharmacotherapy of brain tumors. Future Oncol 1(6):747–754PubMedCrossRef
99.
Sanderson BJ, Shield AJ (1996) Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 355(1–2):41–57PubMedCrossRef
100.
Goldwirt L et al (2013) Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. Biomed Chromatogr 27(7):889–893PubMedCrossRef
101.
Trinh VA, Patel SP, Hwu WJ (2009) The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493–499PubMedCrossRef
102.
Choi JS, Kim CS, Berdis A (2018) Inhibition of translesion DNA synthesis as a novel therapeutic strategy to treat brain cancer. Cancer Res 78(4):1083–1096PubMedCrossRef
103.
Becher OJ et al (2008) Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 68(7):2241–2249PubMedCrossRef
104.
Singec I et al (2006) Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods 3(10):801–806PubMedCrossRef
105.
Liu YJ et al (2017) Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation. Oncotarget 8(26):42495–42509PubMedPubMedCentral
106.
Iorio AL et al (2017) Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma. Oncotarget 8(52):89595–89606PubMedPubMedCentralCrossRef
107.
Wang H et al (2017) Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. J Neurosurg 126(2):446–459PubMedCrossRef
108.
Kim SS et al (2015) A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 11(2):301–311PubMedCrossRef
109.
Lan F et al (2016) Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-kappaB-dependent pathway downregulating MGMT expression. Int J Oncol 48(2):559–568PubMedCrossRef
110.
Lan F et al (2015) Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/beta-catenin signaling in glioblastoma. J Neurochem 134(5):811–818PubMedCrossRef
111.
Sinnberg T et al (2009) Inhibition of PI3 K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129(6):1500–1515PubMedCrossRef
112.
113.
Prasad G et al (2011) Inhibition of PI3 K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 13(4):384–392PubMedPubMedCentralCrossRef
114.
Lam FC et al (2018) Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun 9:1991PubMedPubMedCentralCrossRef
115.
Nitta Y et al (2016) Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Cancer Med 5(3):486–499PubMedPubMedCentralCrossRef
116.
Nonnenmacher L et al (2015) RIST: a potent new combination therapy for glioblastoma. Int J Cancer 136(4):E173–E187PubMedCrossRef
117.
Lesueur P et al (2017) Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 8(40):69105–69124PubMedPubMedCentralCrossRef
118.
Lesueur P et al (2018) Radiosensitization effect of talazoparib, a parp inhibitor, on glioblastoma stem cells exposed to low and high linear energy transfer radiation. Sci Rep 8:3664PubMedPubMedCentralCrossRef
119.
120.
Parrish KE et al (2015) Efflux transporters at the blood–brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther 355(2):264–271PubMedPubMedCentralCrossRef
121.
122.
Park J et al (2017) Expression of immune checkpoint molecules on tumor infiltrating lymphocytes in glioblastoma multiforme. J Immunol 198(1):196CrossRef
123.
Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4(+) T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158–2167PubMedCrossRef
124.
125.
Zeng J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343–349PubMedPubMedCentralCrossRef
126.
Raychaudhuri B et al (2015) Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol 122(2):293–301PubMedCrossRef
127.
Raychaudhuri B et al (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13(6):591–599PubMedPubMedCentralCrossRef
128.
Kamran N et al (2017) Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol Ther 25(1):232–248PubMedPubMedCentralCrossRef
129.
Jachimczak P et al (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65(3):332–337PubMedCrossRef
130.
Schneider T et al (2008) Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195(1–2):21–27PubMedCrossRef
131.
Mathews Griner LA et al (2014) High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 111(6):2349–2354PubMedCrossRefPubMedCentral
132.
133.
134.
Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6):285–290PubMed
135.
Bliss CI (1939) The toxicity of poisons applied jointly 1. Ann Appl Biol 26(3):585–615CrossRef
136.
Yadav B et al (2015) Searching for drug synergy in complex dose–response landscapes using an interaction potency model. Comput Struct Biotechnol J 13:504–513PubMedPubMedCentralCrossRef
Metadata
Title
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Authors
Debarati Ghosh
Saikat Nandi
Sonali Bhattacharjee
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2018
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-018-0211-8

Other articles of this Issue 1/2018

Clinical and Translational Medicine 1/2018 Go to the issue

Research

Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

Research

Viral antigens detectable in CSF exosomes from patients with retrovirus associated neurologic disease: functional role of exosomes

Review

Pros and cons of mouse models for studying osteoarthritis

Review

The impact of modifiable risk factor reduction on childhood asthma development

Review

Potential important roles and signaling mechanisms of YPEL4 in pulmonary diseases

Research

Biobank integration of large-scale clinical and histopathology melanoma studies within the European Cancer Moonshot Lund Center